Rekvina Labs

Which are the latest news on Rekvina Labs?

Why is Rekvina Labs Ltd falling/rising?

As of 05-Sep, Rekvina Labs Ltd's stock price is rising to Rs. 53.83, up 1.99%, supported by strong performance against the Sensex and a 10-day gain streak of 29.03%. Despite a decline in investor participation, the stock remains liquid and is trading above key moving averages, indicating a bullish trend.

As of 05-Sep, Rekvina Labs Ltd's stock price is rising, currently at Rs. 53.83, reflecting an increase of 1.05 (1.99%). This upward movement is supported by several factors. The stock has outperformed the Sensex, which has declined by 0.97% over the past week, while Rekvina Labs has surged by 10.35% in the same period. Over the last month, the stock has shown an impressive increase of 113.19%, contrasting sharply with the Sensex's drop of 2.44%.<BR><BR>Today, Rekvina Labs reached a new 52-week high of Rs. 53.83, indicating strong market interest. The stock has been on a consecutive gain streak for the last 10 days, accumulating a total return of 29.03% during this period. Furthermore, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a strong bullish trend.<BR><BR>However, it is worth noting that there has been a decline in investor participation, with delivery volume falling by 28.19% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, indicating that the overall positive momentum is likely driving the price increase.

Who are in the management team of Rekvina Labs?

The management team of Rekvina Labs consists of Amit Shah (Director), Mukesh Shah (Director), Vibha Mukesh Shah (Additional Director), and Mahendra Shantilal Dalal (Additional Director).

The management team of Rekvina Labs includes the following individuals:<BR><BR>1. Amit Shah - Director<BR>2. Mukesh Shah - Director<BR>3. Vibha Mukesh Shah - Additional Director<BR>4. Mahendra Shantilal Dalal - Additional Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Rekvina Labs do?

Rekvina Labs Ltd is an Indian pharmaceutical company focused on producing formulations and offering contract research and manufacturing services, with a market cap of INR 54 Cr and recent quarterly net sales of 1 Cr. Established in 1988, it has grown significantly in the industry.

Overview: <BR>Rekvina Labs Ltd is an integrated Indian pharmaceutical company operating in the micro cap market, specializing in the production of pharmaceutical formulations and providing contract research and manufacturing services.<BR><BR>History: <BR>Rekvina Labs Limited was incorporated on 1st November 1988. It has evolved from a small domestic company in the mid-1980s to a significant player in the pharmaceutical industry, with reported sales exceeding Rs 20 Crore. The latest quarterly results indicate net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 54 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.22 <BR>Return on Equity: 25.00% <BR>Price to Book: -54.22<BR><BR>Contact Details: <BR>Address: 328 Paradise Complex, Sayajigunj Vadodara Gujarat : 390005 <BR>Tel: 91-265-2362966 <BR>Email: rekvina@gmail.com <BR>Website: http://www.rekvinalaboratories.com

Who are the peers of the Rekvina Labs?

Rekvina Labs' peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Lupin, Dr Reddy's Labs, Cresanto Global, Sang Froid Labs, and Vardhaman Labs. Sun Pharma and Lupin show excellent growth and management quality, while Divi's Lab has the highest 1-year return at 51.10%, and Cipla has the lowest at -10.92%.

Peers: The peers of Rekvina Labs are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Lupin, Dr Reddy's Labs, Cresanto Global, Sang Froid Labs, and Vardhaman Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Lupin, and Dr Reddy's Labs, while the rest do not qualify. Growth is excellent at Sun Pharma.Inds. and Lupin, average at Torrent Pharma and Dr Reddy's Labs, and below average at Divi's Lab. and Cipla, with the rest not qualifying. Excellent capital structure is noted at Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while good capital structure is found at Torrent Pharma and Lupin, and the rest do not qualify.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.10%, while Cipla has the lowest at -10.92%, with Rekvina Labs' 1-year return being not available for comparison. Additionally, Dr Reddy's Labs and Cipla have negative six-month returns.

Should I buy, sell or hold Rekvina Labs Ltd?

When is the next results date for Rekvina Labs Ltd?

The next results date for Rekvina Labs Ltd is 13 August 2026.

The next results date for Rekvina Labs Ltd is scheduled for 13 August 2026.

Are Rekvina Labs Ltd latest results good or bad?

Rekvina Labs Ltd's latest results show mixed performance, with a 105.71% revenue increase and a 50% reduction in net loss, but ongoing challenges like negative book value and persistent losses raise concerns about its financial stability and profitability. Overall, the outlook remains cautious despite some positive metrics.

Rekvina Labs Ltd's latest results present a mixed picture. On one hand, there has been a notable improvement in certain metrics; for instance, the company reported a revenue of ₹0.72 crores in Q4 FY26, which is a significant sequential growth of 105.71% compared to the previous quarter. Additionally, the net loss has improved by 50% quarter-over-quarter, now standing at ₹0.06 crores. The operating margin has also shown improvement, moving from -34.29% to -8.33%.<BR><BR>However, despite these positive changes, the company continues to face significant challenges. It has a negative book value, meaning its liabilities exceed its assets, which raises serious concerns about its financial health. The persistent net losses and lack of a clear path to profitability indicate ongoing operational difficulties. Moreover, the stock has experienced considerable volatility and has declined significantly over the past month, reflecting growing investor skepticism.<BR><BR>Overall, while there are signs of improvement in revenue and loss reduction, the fundamental issues regarding profitability and financial stability remain a concern, leading to a cautious outlook on the company's performance.